NO20035121D0 - Ny anvendelse - Google Patents

Ny anvendelse

Info

Publication number
NO20035121D0
NO20035121D0 NO20035121A NO20035121A NO20035121D0 NO 20035121 D0 NO20035121 D0 NO 20035121D0 NO 20035121 A NO20035121 A NO 20035121A NO 20035121 A NO20035121 A NO 20035121A NO 20035121 D0 NO20035121 D0 NO 20035121D0
Authority
NO
Norway
Prior art keywords
new use
new
Prior art date
Application number
NO20035121A
Other languages
English (en)
Other versions
NO20035121L (no
Inventor
Douglas William Pierre Hay
Gareth John Sanger
Yadataka Yamada
Original Assignee
Smithkline Beecham Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0112208A external-priority patent/GB0112208D0/en
Priority claimed from GB0129268A external-priority patent/GB0129268D0/en
Application filed by Smithkline Beecham Co filed Critical Smithkline Beecham Co
Publication of NO20035121L publication Critical patent/NO20035121L/no
Publication of NO20035121D0 publication Critical patent/NO20035121D0/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
NO20035121A 2001-05-18 2003-11-17 Ny anvendelse NO20035121D0 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0112208A GB0112208D0 (en) 2001-05-18 2001-05-18 New use
GB0129268A GB0129268D0 (en) 2001-12-06 2001-12-06 Novel use
PCT/US2002/015911 WO2002094187A2 (en) 2001-05-18 2002-05-17 Novel use

Publications (2)

Publication Number Publication Date
NO20035121L NO20035121L (no) 2003-11-17
NO20035121D0 true NO20035121D0 (no) 2003-11-17

Family

ID=26246093

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20035121A NO20035121D0 (no) 2001-05-18 2003-11-17 Ny anvendelse

Country Status (19)

Country Link
EP (1) EP1387687A4 (no)
JP (1) JP2004534761A (no)
KR (1) KR20040016865A (no)
CN (1) CN1269483C (no)
AR (1) AR045879A1 (no)
AU (1) AU2002303811B2 (no)
BR (1) BR0209662A (no)
CA (1) CA2447063A1 (no)
CZ (1) CZ20033115A3 (no)
HU (1) HUP0400966A2 (no)
IL (1) IL158701A0 (no)
MX (1) MXPA03010509A (no)
MY (1) MY134211A (no)
NO (1) NO20035121D0 (no)
NZ (1) NZ529462A (no)
PE (1) PE20021067A1 (no)
PL (1) PL367308A1 (no)
TW (1) TWI243678B (no)
WO (1) WO2002094187A2 (no)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
BR122018074353B8 (pt) 2003-01-28 2021-07-27 Ironwood Pharmaceuticals Inc composição farmacêutica, polipeptídeo e métodos para a produção dos mesmos
ATE387189T1 (de) * 2004-03-30 2008-03-15 Smithkline Beecham Corp Sprühgetrocknete pharmazeutische zusammensetzungen
WO2005100997A2 (en) * 2004-04-16 2005-10-27 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with tachykinin receptor 3 (tacr3)
PE20070546A1 (es) * 2005-09-30 2007-07-04 Smithkline Beecham Corp Composiciones farmaceuticas de talnetant
TW200804288A (en) 2005-12-12 2008-01-16 Astrazeneca Ab Alkylsulphonamide quinolines
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
CN101772513B (zh) 2007-06-04 2013-11-13 协同医药品公司 有效用于胃肠功能紊乱、炎症、癌症和其他疾病治疗的鸟苷酸环化酶激动剂
ES2522968T3 (es) 2008-06-04 2014-11-19 Synergy Pharmaceuticals Inc. Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
JP2011528375A (ja) 2008-07-16 2011-11-17 シナジー ファーマシューティカルズ インコーポレイテッド 胃腸障害、炎症、癌、およびその他の障害の治療のために有用なグアニル酸シクラーゼのアゴニスト
WO2018129556A1 (en) 2017-01-09 2018-07-12 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
EP3939964A1 (en) 2008-12-31 2022-01-19 Ardelyx, Inc. Combinations for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
KR200452372Y1 (ko) * 2010-05-14 2011-02-22 서일수 건설용 리프트의 통신선 지지장치
KR101034774B1 (ko) * 2010-07-30 2011-05-17 (주)챔피온코리아 와이어로프를 이용한 리프트 장치
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
AU2013304812B2 (en) 2012-08-21 2016-06-09 Ardelyx, Inc. Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
US10376481B2 (en) 2012-08-21 2019-08-13 Ardelyx, Inc. Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
JP2016514671A (ja) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼのアゴニストおよびその使用
AU2014235209B2 (en) 2013-03-15 2018-06-14 Bausch Health Ireland Limited Guanylate cyclase receptor agonists combined with other drugs
JP6377132B2 (ja) 2013-04-12 2018-08-22 アーデリクス，インコーポレーテッド Ｎｈｅ３結合化合物およびリン酸輸送の阻害方法
US9475773B2 (en) 2013-04-19 2016-10-25 Astrazeneca Ab NK3 receptor antagonist compound (NK3RA) for use in a method for the treatment of polycystic ovary syndrome (PCOS)
WO2014197720A2 (en) 2013-06-05 2014-12-11 Synergy Pharmaceuticals, Inc. Ultra-pure agonists of guanylate cyclase c, method of making and using same
JP2020505333A (ja) 2017-01-09 2020-02-20 アルデリックス， インコーポレイテッド Ｎｈｅ媒介性アンチポートの阻害薬
MA47207A (fr) 2017-01-09 2019-11-13 Ardelyx Inc Composés utiles pour le traitement de troubles du tractus digestif

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2719311B1 (fr) * 1994-03-18 1998-06-26 Sanofi Sa Composés antagonistes sélectifs du récepteur NK3 humain et leur utilisation comme médicaments et outils de diagnostic.
US5434158A (en) * 1994-04-26 1995-07-18 Merck & Co., Inc. Spiro-substituted azacycles as neurokinin-3 antagonists
AR004735A1 (es) * 1995-11-24 1999-03-10 Smithkline Beecham Spa Quinoleina 4-amido sustituida, un procedimiento para su preparacion, una composicion farmaceutica que los contiene y el uso de los mismos para lapreparacion de un medicamento.
WO1998052942A1 (en) * 1997-05-23 1998-11-26 Smithkline Beecham S.P.A. Quinoline-4-carboxamide derivatives as nk-2 and nk-3 receptor antagonists
IL143137A0 (en) * 1998-11-20 2002-04-21 Smithkline Beecham Spa Quinoline-4-carboxamide derivatives as nk-3 and nk-2 receptor antagonists

Also Published As

Publication number Publication date
CN1269483C (zh) 2006-08-16
EP1387687A2 (en) 2004-02-11
AR045879A1 (es) 2005-11-16
HUP0400966A2 (hu) 2004-08-30
MXPA03010509A (es) 2004-03-02
TWI243678B (en) 2005-11-21
CA2447063A1 (en) 2002-11-28
PE20021067A1 (es) 2003-02-02
BR0209662A (pt) 2004-04-20
EP1387687A4 (en) 2006-07-05
WO2002094187A2 (en) 2002-11-28
PL367308A1 (en) 2005-02-21
AU2002303811B2 (en) 2005-07-07
KR20040016865A (ko) 2004-02-25
NO20035121L (no) 2003-11-17
WO2002094187A3 (en) 2003-05-30
NZ529462A (en) 2005-07-29
MY134211A (en) 2007-11-30
CZ20033115A3 (cs) 2004-09-15
JP2004534761A (ja) 2004-11-18
CN1509175A (zh) 2004-06-30
IL158701A0 (en) 2004-05-12

Similar Documents

Publication Publication Date Title
NO20023616L (no) Ny anvendelse
IS7016A (is) Ný 4-anilínókínólín-3-karboxamíð
ATE524462T1 (de) C5-modifizierte indazolylpyrrolotriazine
NO20035121D0 (no) Ny anvendelse
DE50103741D1 (de) Welle-Nabe-Verbindung
ATE335486T1 (de) Hydrazono-malonitrile
DE1319930T1 (de) Coriolismassendurchflussmesser
ATE355059T1 (de) Isoxazolopyridinone
DE50201862D1 (de) Messwandler
NO20033919D0 (no) Ny anvendelse
ATE319694T1 (de) Phenylalkyne
ATA18372001A (de) Gelenksbolzenbaueinheit
DE50108381D1 (de) Synchronisierschaltungsanordnung
DE10295006D2 (de) Bauwerksabdichtung
ATA13992002A (de) Schlackengranulierungsanlage
ATE345337T1 (de) Delta1 -pyrroline
AT500276B8 (de) Radschwenksystem
ATA7462001A (de) Radspannwerk
SE0104065D0 (sv) New use
SE0104092D0 (sv) New use
SE0100062D0 (sv) New use
SE0100798D0 (sv) New use
SE0101160D0 (sv) New use
SE0102574D0 (sv) New Use
SE0103291D0 (sv) New use

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application